BioCryst Pharmaceuticals, Inc. (BCRX)
7.235
-0.08
(-1.16%)
USD |
NASDAQ |
Nov 20, 16:00
7.235
0.00 (0.00%)
After-Hours: 19:22
BioCryst Pharmaceuticals Gross Profit (TTM) : 938.98M for Sept. 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 938.98M |
| June 30, 2026 | 917.38M |
| March 31, 2026 | 863.71M |
| December 31, 2025 | 854.37M |
| September 30, 2025 | 582.83M |
| June 30, 2025 | 539.50M |
| March 31, 2025 | 486.55M |
| December 31, 2024 | 436.98M |
| September 30, 2024 | 403.23M |
| June 30, 2024 | 374.87M |
| March 31, 2024 | 348.72M |
| December 31, 2023 | 325.10M |
| September 30, 2023 | 310.41M |
| June 30, 2023 | 297.05M |
| March 31, 2023 | 280.86M |
| December 31, 2022 | 262.80M |
| September 30, 2022 | 232.71M |
| June 30, 2022 | 201.04M |
| March 31, 2022 | 185.50M |
| December 31, 2021 | 149.13M |
| September 30, 2021 | 106.32M |
| June 30, 2021 | 70.74M |
| March 31, 2021 | 21.32M |
| December 31, 2020 | 12.87M |
| September 30, 2020 | 46.27M |
| Date | Value |
|---|---|
| June 30, 2020 | 43.26M |
| March 31, 2020 | 44.51M |
| December 31, 2019 | 44.37M |
| September 30, 2019 | 9.744M |
| June 30, 2019 | 9.41M |
| March 31, 2019 | 20.42M |
| December 31, 2018 | 19.76M |
| September 30, 2018 | 20.90M |
| June 30, 2018 | 27.17M |
| March 31, 2018 | 17.82M |
| December 31, 2017 | 23.22M |
| September 30, 2017 | 26.08M |
| June 30, 2017 | 26.11M |
| March 31, 2017 | 27.88M |
| December 31, 2016 | 23.48M |
| September 30, 2016 | 21.50M |
| June 30, 2016 | 23.60M |
| March 31, 2016 | 44.33M |
| December 31, 2015 | 46.34M |
| September 30, 2015 | 47.19M |
| June 30, 2015 | 40.75M |
| March 31, 2015 | 16.77M |
| December 31, 2014 | 13.40M |
| September 30, 2014 | 18.49M |
| June 30, 2014 | 17.62M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Halozyme Therapeutics, Inc. | 1.371B |
| Neurocrine Biosciences, Inc. | 3.569B |
| Agenus, Inc. | 131.74M |
| Amgen, Inc. | 28.84B |
| Anika Therapeutics, Inc. | 78.26M |